Caris Life Sciences, Inc. (CAI) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 40
- Profitability 95
- Business Quality 65
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 45/100 — Speculative
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Caris Life Sciences, Inc. (CAI) is a Biotechnology company in the Healthcare sector. Compound Radar rates Caris Life Sciences, Inc. 45/100 (Speculative) due to solid business quality, strong revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Strong
- Balance Sheet Stretched
- Valuation Elevated
Financial highlights
Valuation
- P/E 2.59
- Forward P/E 65.68
- EV/Revenue 6.82
Profitability
- Revenue Growth 45.4%
- Gross Margin 69.8%
- Operating Margin 10.2%
- Net Margin 10.6%
- ROE 20.1%
Financial strength
- Cash $793.12M
- Debt $452.40M
- Net Cash $340.71M
- Free Cash Flow $66.89M
- Current Ratio 5.53
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Caris Life Sciences, Inc. (CAI).